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This review systematically assessed the evidence on the clinical and cost-effectiveness of cardioprotection against the toxic effects of
anthracyclines given to children with cancer. We searched eight electronic databases, including Medline and the Cochrane Library,
from inception to January 2006 for systematic reviews and randomised controlled trials that reported death, heart failure, arrhythmias
or measures of cardiac performance associated with cardioprotective technologies compared with standard treatment in children
treated for cancer with anthracyclines. Economic evaluations were also sought. Inclusion criteria, data extraction and quality
assessment were undertaken by standard methodology. Four randomised controlled trials met the inclusion criteria of the review;
each had methodological limitations. No economic evaluations were identified. Studies were combined through narrative synthesis.
One trial found that continuous infusion of doxorubicin did not offer any cardioprotection over rapid infusion. One suggested that
continuous infusion of daunorubicin provoked less cardiotoxicity than rapid infusion. One concluded that dexrazoxane reduces
cardiac injury during doxorubicin therapy and one reported a protective effect of coenzyme Q10 on cardiac function during
anthracycline therapy. The evidence on the effectiveness of cardioprotective technologies in children is limited in quality and quantity
thus making conclusions difficult. This is surprising given the importance of anthracycline use in children with cancer. Further long-term
research, which includes relevant outcome measures, is needed to determine whether technologies influence the development of
cardiac damage without limiting the antitumour efficacy of anthracyclines.
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Cytotoxic antibiotics, known as anthracyclines, are highly potent
chemotherapeutic agents that have been widely used in the
treatment of paediatric malignancies. Their introduction has led
to the successful treatment of childhood cancer with improved
survival rates now approaching 75% (Curry et al, 2006). There are
an estimated 270 000 survivors of childhood cancer in the USA
(Hewitt et al, 2003) and more than 20 000 in the UK (National
Institute for Health and Clinical Excellence, 2005), half of whom
are likely to have been treated with anthracyclines. However, as
children are surviving cancer for longer, a cost of treatment, in the
form of late sequelae relating to both the disease and as a
consequence of therapy, has become apparent (Curry et al, 2006).
Nearly two thirds of survivors have one or more related chronic
medical problems and may require multidisciplinary care (Curry
et al, 2006). A particular limitation of anthracycline therapy is
dose-dependent cardiotoxicity that can lead to clinical heart failure
(Bonadonna and Monfardini, 1969; Bu’Lock et al, 1996).
The problem of anthracycline-induced clinical heart failure (A-
CHF) is an important public health concern as it may not be seen
for many years and remains a life-long threat. It is of particular
importance in children who may survive for decades after
successful antineoplastic treatment. As survival rates continue to
improve, the resources needed to monitor and care for survivors
will also continue to increase.
The precise mechanism underlying A-CHF is not fully under-
stood but is thought to be due, in part, to lipid peroxidation and
the generation of free radicals by anthracycline–iron complexes
(Myers, 1998). The heart is particularly vulnerable to free radical
injury because protective enzymes are present at lower levels than
in other tissues (Myers, 1998). The damage to myocardial cells may
eventually lead to irreversible heart failure.
It is thought that an effective way to avoid the cardiotoxic effects
of anthracyclines is to prevent cardiac injury during chemother-
apy. Three approaches have been attempted: firstly by decreasing
myocardial concentrations of anthracyclines and their metabolites
by dose limitation or schedule modification (Lipshultz et al, 1998;
Levitt et al, 2004); secondly by developing less cardiotoxic
anthracycline derivatives and formulations (Batist et al, 2001)
and thirdly by the administration of cardioprotective agents
during or after chemotherapy to attenuate the effects of
anthracyclines on the heart (Hellmann, 1996). The main issue of
concern is that the cardioprotective technology reduces the heart
damage caused by anthracyclines without reducing the antitumour
efficacy and without causing other toxic effects.Received 20 September 2006; accepted 27 November 2006
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Owing to the uncertainty about the effectiveness of cardiopro-
tection and the importance of trying to reduce the impact of the A-
CHF in terms of cost to the children receiving anthracyclines for
cancer, their families and carers, and to the National Health
Service (NHS), we were commissioned by the NHS Health
Technology Assessment Programme to assess the evidence in the
literature. We conducted a systematic review of cardioprotection
against the toxic effects of anthracyclines given to children with
cancer. This paper summarises the findings of the systematic
review and discusses its implications.
METHODS
Eight electronic databases (including Medline, Cochrane Database
of Systematic Reviews, Cochrane Controlled Trials register,
Embase) were searched from inception for periods up to January
2006 (search strategies available on request). Additional studies
were identified through searching bibliographies of related
publications and through contact with experts. Further details
are available elsewhere (Bryant et al, in press).
Randomised controlled trials published in English language
were sought that compared cardioprotective technologies with
standard treatment protocols or other cardioprotective agents;
included children aged up to 18 being treated for cancer with
anthracyclines; and used patient-based primary outcomes of
mortality, heart failure, arrhythmia or measures of cardiac
performance. Systematic reviews of individual randomised trials
and published economic evaluations were also sought. The quality
of randomised controlled trials was assessed using criteria
developed by the Centre for Reviews and Dissemination (CRD,
2001). Inclusion criteria, decisions about quality criteria and data
extraction were applied independently by two reviewers, with any
differences in opinion resolved through discussion. Studies of
clinical effectiveness were combined through narrative synthesis
with full tabulation of included studies. Meta-analysis was not
appropriate owing to heterogeneity of interventions.
RESULTS
Quantity and quality of research
Of 994 titles and abstracts, four randomised controlled trials met
the inclusion criteria (Steinhertz et al, 1993; Iarussi et al, 1994;
Lipshultz et al, 2002, 2004) (see Table 1). Each considered a
different cardioprotective intervention; two considered continuous
infusion vs rapid (bolus) infusion, one each of doxorubicin
(Lipshultz et al, 2002) and daunorubicin (Steinhertz et al, 1993),
and two considered cardioprotective agents, one each of coenzyme
Q10 (Iarussi et al, 1994) and dexrazoxane (Lipshultz et al, 2004).
No cost-effectiveness studies considering cardioprotection in
children receiving anthracycline therapy for cancer were identified.
When judged using standard criteria for assessing methodolo-
gical quality, the randomised controlled trials (RCTs) were of poor
quality (see Table 2). All were described as randomised but it is not
known if treatment allocation was concealed and details of the
methods used are mostly unknown. Eligibility criteria were
specified in all cases although only partially in one trial. Details
of whether outcome assessors were blinded to treatment allocation
was adequate in two trials (Lipshultz et al, 2002, 2004); patient
blinding to treatment allocation was unknown (Steinhertz et al,
1993; Iarussi et al, 1994; Lipshultz et al, 2002) or inadequate
(Lipshultz et al, 2004). Results were adequately presented with
point estimates and a measure of variability in two trials (Iarussi
et al, 1994; Lipshultz et al, 2004) and an intention-to-treat analysis
in one (Iarussi et al, 1994). Withdrawals and dropouts are
adequately described with numbers and reasons in two trials
(Iarussi et al, 1994; Lipshultz et al, 2004).
Assessment of effectiveness
Continuous infusion vs bolus infusion of Doxorubicin (Lipshultz
et al, 2002) This study looked at moderate dose doxorubicin
administration by continuous infusion (48 h) or by bolus infusion
in children with newly diagnosed acute lymphoblastic leukaemia
and was designed to detect a reduction in toxicity. After
doxorubicin treatment, no significant difference was demonstrated
between the two groups for any cardiac characteristic measured
(see Table 3). Both groups showed abnormalities of left ventricular
structure and function compared with normal reference data and
baseline. For example, median left ventricular fractional short-
ening fell significantly by approximately two s.d. in both the
continuous infusion and bolus infusion groups, but there was no
statistical difference between the groups. Left ventricular contrac-
tility was depressed in both groups (for bolus patients, median z-
score¼0.70, P¼ 0.006, when compared with normal population;
for continuous infusion patients, median z-score¼0.765,
P¼ 0.005, when compared with normal population). Both groups
showed progressive but mild subclinical cardiotoxicity. There was
no difference in event-free survival between the groups.
Continuous infusion vs bolus infusion of Daunorubicin (Steinhertz
et al, 1993) This pilot study compared the antileukaemic efficacy
of continuous infusion of daunorubicin with bolus infusion in
children with newly diagnosed acute lymphoblastic leukaemia and
reported cardiac function in a subgroup of patients. Less
sophisticated echocardiographic techniques were used than in
the study described above (Lipshultz et al, 2002). A median change
in left ventricular fractional shortening of 6.5 units is reported
for participants who received a bolus infusion of daunorubicin and
þ 1 unit in those receiving the continuous infusion of daunor-
ubicin (see Table 3). It is not reported whether the change is
statistically significant between the two groups.
Four of the 18 participants who received the bolus infusion of
daunorubicin were identified as having an important deterioration
in cardiac function (defined arbitrarily as a decrease of left
ventricular fractional shortening on two consecutive evaluations to
abnormal levels (less than 29%) or by 10 or more percentile units
from the baseline level for that particular patient to borderline
function 29% at any time during treatment or follow-up). None of
those who received a continuous infusion of the drug experienced
this level of fractional shortening.
Results suggested that a more rapid cytoreduction occurred
when daunorubicin was delivered by continuous infusion com-
pared with bolus infusion and the study concluded that
‘continuous infusion of daunorubicin had less cardiotoxicity with
faster antileukaemic activity than bolus infusion’. However, not all
results are reported separately for the different treatment groups
so there are no comparable groups for statistical comparison for
leukaemic cell reduction and cardiac function. We are not aware of
published follow-up data regarding cardiac status for these
patients.
Anthracycline therapy with or without coenzyme Q10 (Iarussi et al,
1994) This small study evaluated the protective effect of
Table 1 Clinical effectiveness studies
Study, Author and dateIntervention and comparator
Lipshultz et al (2002) Continuous infusion of doxorubicin vs bolus infusion
Steinhertz et al (1993) Continuous infusion of daunorubicin vs bolus infusion
Iarussi et al (1994) Co-enzyme Q10 vs no co-enzyme Q10
Lipshultz et al (2004) Dexraxozane vs no dexraxozane
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coenzyme Q10 on anthracycline-induced cardiotoxicity in children
diagnosed with acute lymphoblastic leukaemia or non-Hodgkin’s
lymphoma. Two main cardiac outcomes, left ventricular fractional
shortening and septal wall structure and function, were reported
(see Table 3).
After anthracycline treatment, percentage left ventricular frac-
tional shortening (%LVFS) was significantly decreased in both
groups of children. In the group of children receiving coenzyme
Q10 %LVFS decreased from 40.3674.60 at baseline to 35.8275.02
at the end of therapy (Po0.05), whereas in the group that did not
Table 2 Quality assessment of included experimental studies
Criteria
Lipshultz
et al (2002)
Steinhertz
et al (1993)
Iarussi et al
(1994)
Lipshultz
et al (2004)
Was the assignment to the treatment groups really random? Unknown Unknown Unknown Adequate
Was the treatment allocation concealed? Unknown Unknown Unknown Unknown
Were the groups similar at baseline in terms of prognostic factors? Reported only
for the
participants for
whom there
were outcome
data.
Unknown Reported Reported
Were the eligibility criteria specified? Adequate Adequate Partial Adequate
Were outcome assessors blinded to the treatment allocation? Adequate Unknown Unknown Adequate
Was the care provider blinded? Unknown Unknown Unknown No
Cointerventions described Inadequate Adequate Partial Partial
Was the patient blinded? Unknown Unknown Unknown No
Were the point estimates and measure of variability presented for the
primary outcome measure?
Partial Inadequate Adequate Adequate
Did the analyses include an intention to treat analysis? Inadequate Inadequate Adequate Inadequate
Were withdrawals and dropouts completely described? Inadequate Inadequate Adequate Adequate
Table 3 Summary of effectiveness of cardioprotection from included RCTs
Study Intervention Patients Follow-up Cardiac outcomes Survival
Lipshultz et al
(2002)
DOX bolus
(n¼ 62) vs DOX
continuous infusion
(n¼ 55)
ALL 0–56 months LVFS median z-score after treatment, DOX
bolus 0.47, DOX infusion 0.44 (P¼ 0.60);
LV contractility median z-score after treatment,
DOX bolus 0.70, DOX infusion 0.765
(P¼ 0.99); No congestive heart failure in either
group
5-year EFS (excluding early treatment
failures, mean7s.e.), DOX bolus
89.073.9%, DOX infusion 87.374.5%
(P¼ 0.50); 5-year EFS (including early
treatment failures, mean7s.e.), DOX
bolus 8074%, DOX infusion 8674%
(P¼ 0.23)
Steinhertz et al
(1993)
DAUN bolus
(n¼ 22) vs DAUN
continuous infusion
(n¼ 22)
ALL Minimum 25
months
Change in LVFS, DAUN bolus 6.5 units,
DAUN infusion+1 unit (P-value not reported);
Important deterioration in cardiac function,
DAUN bolus 4/18, DAUN infusion 0/18
(P¼ 0.10)
With only two relapses at the time of
reporting the authors were unable to
see any effects on long-term survival
Iarussi et al
(1994)
Addition of
coenzyme Q10
(n¼ 10) vs no
coenzyme Q10
(n¼ 10)
ALL or NHL Not reported %LVFS (mean7s.d.) decrease from baseline to
end value, coenzyme Q10 40.3674.60–
35.8275.02, no coenzyme Q10 39.8974.37–
33.4373.46 (P-value not reported but
difference described as significant); %SWT
(mean7s.d.) decrease from baseline to end
value, Coenzyme Q10 44.10713.20–
40.10715.30 (NS), no coenzyme Q10
46.10710.10–27.0718.54 (Po0.01); No
significant changes in left ventricular posterior
wall thickening reported for either group
Not reported
Lipshultz et al
(2004)
DOX (n¼ 101) vs
DZX and DOX
(n¼ 105)
ALL Median 2.7
years
Patients with elevated cTnT levels at any time,
DOX 50% (95% CI 38, 62),DZX and DOX
21% (95% CI 13, 31) (Po0.001); Multiple
elevations, DOX 37% (95% CI 26, 49), DZX
and DOX 12% (95% CI 6, 21) (Po0.001); Any
extreme elevation, DOX 32% (95% CI 21, 43),
DZX and DOX 10% (95% CI 4, 18)
(Po0.001); Echocardiographic data, no
significant differences between groups in LVFS,
LVD or LVC; LVFS was significantly depressed
in both groups during and after treatment
(mean z-score 1.06, Po0.001)
EFS at 2.5 year, DOX 83%, DZX and
DOX 83% (P¼ 0.87)
ALL¼ acute lymphoblastic leukaemia; DAUN¼ daunorubicin; DOX¼ doxorubicin; DZX¼ dexrazoxane; EFS¼ event-free survival; LVFS¼ left ventricular fractional shortening;
NHL¼Non-Hodgkin’s lymphoma; NS¼ not significant; SWT¼ septal wall thickening.
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receive coenzyme Q10 %LVFS decreased from 39.8974.37 at
baseline to 33.4373.46 at the end of therapy (Po0.002). The study
reports that ‘mean %LVFS was significantly lower in the group that
received coenzyme Q10 compared to the mean value in the group
that did not receive coenzyme Q10’, but probably refers to mean
reduction in %LVFS, which was lower in treated patients although
no P-value is given for this comparison. The LVFS parameter is
never reported to be below the normal value. No statistical
reduction in the percentage septal wall thickening (%SWT) was
reported in the group that received coenzyme Q10. In the group
that did not receive coenzyme Q10 %SWT was statistically
decreased from 46.10710.1 at baseline to 27.00718.54 at end of
the therapy (Po0.01). No between-group statistical comparison is
reported. Again, we are not aware of published follow-up data for
these patients.
Doxorubicin therapy with or without dexrazoxane (Lipshultz et al,
2004) This study was conducted to determine whether dexrazox-
ane therapy reduces myocardial injury as measured by serum
cardiac troponin T (cTnT) levels in children with newly diagnosed
acute lymphoblastic leukaemia being treated with doxorubicin (see
Table 3). Echocardiographic results were available for a subgroup
of patients who underwent randomisation.
Significantly, fewer patients in the group given dexrazoxane and
doxorubicin compared with patients in the doxorubicin group had
any elevations in cTnT (21 vs 50%, Po0.001), any extreme
elevations in cTnT (10 vs 32%, Po0.001), or multiple elevations in
cTnT (12 vs 37%, Po0.001).
There were no significant differences between the children who
received doxorubicin alone and those who received dexrazoxane
and doxorubicin in terms of mean left ventricular dimension,
fractional shortening or contractility, before, during or after
therapy. Fractional shortening was significantly depressed in both
randomised groups during and after treatment (mean z-score,
1.06; Po0.001).
The rate of event-free survival at 2.5 years was 83% in both
groups and continuous remission was 81% in both groups.
DISCUSSION
This review, guided by an expert advisory panel, considered
systematically the evidence on the clinical and cost-effectiveness of
cardioprotection against the toxic effects of anthracyclines given to
children with cancer. Only randomised controlled trials were
included in the review as the potential for confounding is high,
where children at particular risk of cardiac damage could be
treated differently in terms of drug choice and dose from those at
lower risk. Four randomised controlled trials were found that met
the inclusion criteria of the review.
It is difficult to make conclusions about the effectiveness of
technologies for reducing or preventing anthracycline-induced
cardiotoxicity in children with cancer as the evidence is limited in
both quantity and quality. The four RCTs considered different
interventions and each had methodological limitations that may
impact on results and bring into question the reliability of the
conclusions. The main concern is that not all of the studies report
the effect of the cardioprotective agent in terms of both subclinical
and long-term cardiac damage, which may be subtle, and
antitumour effectiveness through event-free survival. Two RCTs
considered continuous infusion vs bolus infusion; one RCT found
that continuous infusion of doxorubicin did not offer cardiopro-
tection over bolus; the other suggested that continuous infusion of
daunorubicin had less cardiotoxicity than bolus infusion but did
not report results separately for all outcomes for the different
treatment arms of the study. Two studies investigated protective
agents; one concluded that dexrazoxane prevents or reduces
cardiac injury as reflected in elevation of a cardiac marker (cTnT)
during doxorubicin therapy for childhood acute lymphoblastic
leukaemia without compromising antileukaemic efficacy of
doxorubicin but it did not provide direct correlation of
echocardiographic abnormality with elevations in cTnT; the other
reported a protective effect of coenzyme Q10 on cardiac function
during anthracycline therapy but did not support this conclusion
with statistical data. Such inconclusive evidence on cardioprotec-
tive interventions has also been found for adults receiving
anthracyclines for cancer (van Dalen et al, 2005).
There is no agreed consensus of the definition of cardiotoxicity
and no standardisation for monitoring cardiac performance. A
range of cardiac measures are reported in the included studies,
which makes comparison of study results difficult. These issues
need to be addressed in order to make future synthesis of evidence
possible. All clinically relevant outcomes are important, including
acute and chronic side effects of cardioprotective measures,
because, for example, the lower peak benefit of continuous
infusion may be offset by damage caused by more prolonged
exposure time (Lipshultz et al, 2002). Overall, the most important
outcome is event-free survival in terms of the whole treatment
protocol. This is because if the cardioprotective agent causes
increased morbidity even without impairing the anthracycline
tumour killing activity, other treatments may not be given in a
timely manner which may have a negative impact on final
outcome.
No cost-effectiveness studies were identified, although costs are
an important issue. Costs associated with anthracycline use in
children with cancer relate to the cost of cardiac surveillance and
the cost of management. All survivors require at least occasional
echocardiography and high-risk patients require more specialist
cardiological assessment, although the nature and frequency of
cardiac surveillance required is controversial. Management costs
include clinical supervision and drug therapy in those with
abnormal cardiac function, the unproven aim being to ameliorate
the progression to irreversible heart failure. In addition, there are
indirect costs associated with sick long-term survivors with cardiac
dysfunction who may be limited in their occupation and
productivity, with reduced quality of life and social independence,
which are important considerations. Technologies to reduce or
prevent cardiotoxicity could influence such costs and lead to either
reduced or increased costs. It may be, for example, that longer
infusion time could be associated with extra costs owing to more
hospitalisations and complications (Lipshultz et al, 2002).
Protocols used for the treatment of childhood cancer are
continually developing with new drugs and new combinations of
drugs proving successful, and these must balance achieving a cure
and minimising side effects. Although the studies identified by this
systematic review do not all reflect current UK treatment
protocols, the risk of cardiotoxicity continues. Current treatment
aims at intensity for high-risk patients and reduced therapy
for low-risk groups. Therefore, there will continue to be some
groups of patients at risk of A-CHF and subclinical toxicity
may be present even in those who have had comparatively safe
doses of anthracyclines. The results of the systematic review
suggest that this problem has not been solved and will continue to
be a major public health concern, especially in the light of
increasing rates of childhood cancer (National Institute for Health
and Clinical Excellence, 2005). In the meantime, anthracycline
dose limitation remains the most effective tool in limiting the
severity of cardiac damage in current clinical practice (Sorensen
et al, 2003).
Further research in the form of well-designed RCTs with
economic evaluations is needed. This should be conducted
within the context of treatment protocols with long-term
follow-up in order to determine cost-effectiveness and whether
the various cardioprotective technologies influence event-free
survival and cardiac outcomes in children with cancer receiving
anthracyclines.
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